Diabetic Gastroparesis Pipeline: Emerging Therapies and Innovations in Gastrointestinal Management | DelveInsight

The treatment landscape for Diabetic Gastroparesis (DG), a debilitating condition characterized by delayed gastric emptying in diabetic patients, is witnessing significant advancements as current therapeutic options remain limited and largely symptom-based. The demand for more effective treatments has prompted the exploration of novel pharmacological agents, neuromodulation techniques, and regenerative therapies to improve gastrointestinal motility and enhance quality of life for DG patients.

DelveInsight's "Diabetic Gastroparesis - Pipeline Insight, 2025" offers a thorough analysis of the ongoing clinical and preclinical development of investigational therapies. The report highlights promising drug candidates, biological treatments, and innovative approaches targeting the underlying pathophysiology of DG. Key therapeutic strategies include prokinetic agents, neurostimulation devices, targeted biologics, and gene therapies aimed at restoring gastric function and addressing the root causes of delayed gastric emptying.

This report provides detailed insights into therapies at all stages of development, examining administration routes, delivery mechanisms, and geographical trial trends. It also explores unmet clinical needs, emerging scientific innovations, regulatory milestones (e.g., breakthrough therapy designations, orphan drug status), and potential strategic partnerships that could redefine the treatment approach for Diabetic Gastroparesis in the near future.

Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic gastroparesis pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Diabetic Gastroparesis Pipeline Report
• DelveInsight's diabetic gastroparesis pipeline analysis depicts a strong space with 6+ active players working to develop 8+ pipeline drugs for diabetic gastroparesis treatment.
• The leading diabetic gastroparesis companies include Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others are evaluating their lead assets to improve the diabetic gastroparesis treatment landscape.
• Key diabetic gastroparesis pipeline therapies in various stages of development include TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
• In April 2025, Vanda Pharmaceuticals accused the FDA of deliberately delaying its request for a hearing on tradipitant's approvability for gastroparesis, blaming internal bureaucracy and recent leadership changes, including the appointment of Commissioner Dr. Martin Makary and agency staffing cuts.
• In January 2025, Vanda Pharmaceuticals accepted the FDA's hearing for the NDA of Tradipitant for gastroparesis, a digestive disorder with no new FDA-approved treatments in over 40 years. Current therapies are often ineffective, and studying new drugs is difficult due to symptom variability and placebo effects.

Request a sample and discover the recent breakthroughs happening in the diabetic gastroparesis pipeline landscape @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Overview
Diabetic Gastroparesis is a form of gastroparesis caused by diabetes. Its symptoms can vary in severity from person to person and may include nausea, vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux, and stomach spasms. This condition is more common in women and individuals who have undergone surgery around the esophagus, stomach, or small intestine, as such procedures can impact the vagus nerve. According to the American College of Gastroenterology (ACG) guidelines, the diagnosis of Diabetic Gastroparesis requires a combination of specific symptoms, signs, and delayed gastric emptying, without gastric outlet obstruction or ulceration. Treatment typically includes nutritional assessment, dietary changes, glycemic control, and the use of prokinetic and antiemetic medications.

Find out more about diabetic gastroparesis medication @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Treatment Analysis: Drug Profile
PCS-12852: Processa Pharmaceuticals
PCS-12852 is an innovative, highly selective 5-HT4 receptor agonist designed to treat gastrointestinal (GI) motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. The drug is currently undergoing Phase II clinical trials for the treatment of Diabetic Gastroparesis.

NG101: Neurogastrx
NG101 is a potent and selective dopamine D2 receptor antagonist that is peripherally restricted. It is in Phase II clinical trials for treating Diabetic Gastroparesis. Preclinical studies from Neurogastrx have demonstrated that, in addition to its strong antiemetic effects, NG101 is also expected to significantly enhance gastric motility, making it a promising candidate for gastroparesis treatment.

Learn more about the novel and emerging diabetic gastroparesis pipeline therapies @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Diabetic Gastroparesis Pipeline Report
• Coverage: Global
• Key Diabetic Gastroparesis Companies: Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.
• Key Diabetic Gastroparesis Pipeline Therapies: TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.

Dive deep into rich insights for drugs used for diabetic gastroparesis treatment; visit @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Gastroparesis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Pipeline: Late-Stage Products (Phase III)
7. Diabetic Gastroparesis Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Gastroparesis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences industry. We provide pharmaceutical companies with tailored, end-to-end solutions to optimize their strategies and enhance business outcomes. With our subscription-based platform, PharmDelve, you can access a comprehensive range of healthcare and pharma market research reports, ensuring informed decision-making and sustained growth.

This release was published on openPR.